Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 2, 2020
Daily News
March 2, 2020
- MHLW Panel Clears Latuda, 1st Japan-Originated Oligonucleotide; Approval Expected in March
March 2, 2020
- Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
- Crysvita Gets FDA’s Priority Review for Tumor-Induced Osteomalacia
March 2, 2020
- Takeda Files Midazolam Oral Solution for Status Epilepticus
March 2, 2020
- Takeda Submits Brigatinib in Japan as Second-Line Treatment for ALK-Positive NSCLC
March 2, 2020
- Pfizer Sales Reps Told to Avoid Doctor Visits, Stay at Home amid Coronavirus Woes
March 2, 2020
- Nichi-Iko Takes Over Marketing Authorization for Etanercept Biosimilar from Kyowa
March 2, 2020
- Otsuka Joins Global Partnership to Eliminate TB
March 2, 2020
- Seikagaku to Acquire Canadian CDMO; Share Transfer Expected by End of March
March 2, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…